Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.
2.

Suboxone misuse along the opiate maintenance treatment pathway.

Furst RT.

J Addict Dis. 2013;32(1):53-67. doi: 10.1080/10550887.2012.759860.

PMID:
23480248
3.

Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.

Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA.

J Gen Intern Med. 2012 Jun;27(6):669-76. doi: 10.1007/s11606-011-1962-8. Epub 2012 Jan 4.

4.

A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.

Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D'Egidio P, Stankova Z, Costa A, Smyth BP, Sakoman S, Wei Y, Strang J.

Addiction. 2012 Jan;107(1):142-51. doi: 10.1111/j.1360-0443.2011.03577.x. Epub 2011 Oct 12.

PMID:
21749526
5.

A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.

Matson SC, Hobson G, Abdel-Rasoul M, Bonny AE.

J Addict Med. 2014 May-Jun;8(3):176-82. doi: 10.1097/ADM.0000000000000035.

PMID:
24695018
6.

HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.

Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S22-32. doi: 10.1097/QAI.0b013e318209751e.

7.

Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.

Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S83-90. doi: 10.1097/QAI.0b013e31820bc9a5.

8.

Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD, Manubay JM, Mogali S, Comer SD.

Pain. 2013 Aug;154(8):1442-8. doi: 10.1016/j.pain.2013.05.004. Epub 2013 May 7.

9.

Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).

Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, Martin JA, Ang A, Baker R, Saxon AJ, Ling W.

J Stud Alcohol Drugs. 2013 Jul;74(4):605-13.

10.

Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.

Rosenblum A, Cruciani RA, Strain EC, Cleland CM, Joseph H, Magura S, Marsch LA, McNicholas LF, Savage SR, Sundaram A, Portenoy RK.

J Opioid Manag. 2012 Nov-Dec;8(6):369-82. doi: 10.5055/jom.2012.0137.

11.

Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.

Lucas GM, Young A, Donnell D, Richardson P, Aramrattana A, Shao Y, Ruan Y, Liu W, Fu L, Ma J, Celentano DD, Metzger D, Jackson JB, Burns D; HPTN 058 study group.

Drug Alcohol Depend. 2014 Sep 1;142:139-45. doi: 10.1016/j.drugalcdep.2014.06.013. Epub 2014 Jun 19.

12.

Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.

Fox AD, Chamberlain A, Sohler NL, Frost T, Cunningham CO.

J Subst Abuse Treat. 2015 Jan;48(1):112-6. doi: 10.1016/j.jsat.2014.07.015. Epub 2014 Aug 7.

13.

Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.

Woodcock EA, Lundahl LH, Greenwald MK.

Drug Alcohol Depend. 2015 Jan 1;146:89-96. doi: 10.1016/j.drugalcdep.2014.11.016. Epub 2014 Nov 26.

15.

Evaluation of buprenorphine dosage adequacy in opioid receptor agonist substitution therapy for heroin dependence: first use of the BUprenorphine-naloxone Dosage Adequacy eVAluation (BUDAVA) questionnaire.

D'Amore A, Romano F, Biancolillo V, Lauro G, Armenante C, Pizzirusso A, Del Tufo S, Ruoppolo C, Auriemma F, Cassese F, Oliva P, Amato P.

Clin Drug Investig. 2012 Jul 1;32(7):427-32. doi: 10.2165/11633230-000000000-00000.

PMID:
22559256
16.

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

Parran TV, Adelman CA, Merkin B, Pagano ME, Defranco R, Ionescu RA, Mace AG.

Drug Alcohol Depend. 2010 Jan 1;106(1):56-60. doi: 10.1016/j.drugalcdep.2009.07.013. Epub 2009 Aug 29.

17.

Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.

Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S33-8. doi: 10.1097/QAI.0b013e3182097537.

18.

Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care.

Egan JE, Netherland J, Gass J, Finkelstein R, Weiss L; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S46-53. doi: 10.1097/QAI.0b013e3182097561.

PMID:
21317594
19.

Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.

Weiss L, Netherland J, Egan JE, Flanigan TP, Fiellin DA, Finkelstein R, Altice FL; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S68-75. doi: 10.1097/QAI.0b013e31820a8226.

PMID:
21317597
20.

A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D, Woody G, Krejci J, Ziedonis D; Buprenorphine Study Protocol Group.

Addiction. 2005 Aug;100(8):1090-100. Erratum in: Addiction. 2006 Sep;101(9):1374.

Supplemental Content

Support Center